News

Biotechnology

Jeff Kagan | Equities.com |

This is my list of the Top CEO Innovators who are changing our world.


Stephen L Kanaval | Equities.com |

ACB, GWPH and Organigram Holdings makes the list.


Edward Kim | Equities.com |

Company seeks to expand the use of Rubraca to patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.


Edward Kim | Equities.com |

All cash deal will add Phase 3 asset for the treatment of moderate-to-severe atopic dermatitis.


Edward Kim | Equities.com |

Merck's blockbuster drug wins another indication in the ongoing cancer battle.


Edward Kim | Equities.com |

Multi-year deal with Acerta Pharma, AstraZeneca's hematology research and development arm.


Edward Kim | Equities.com |

The company is pursuing dermatological therapies, with its lead product candidate in Phase 3 clinical trials for plaque psoriasis.